YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Journal Article
| Authors: | Hormigo, A.; Gu, B.; Karimi, S.; Riedel, E.; Panageas, K. S.; Edgar, M. A.; Tanwar, M. K.; Rao, J. S.; Fleisher, M.; Deangelis, L. M.; Holland, E. C. |
| Article Title: | YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas |
| Abstract: | Purpose: Biomarkers can facilitate diagnosis, monitor treatment response, and assess prognosis in some patients with cancer. YKL-40 and matrix metalloproteinase-9 (MMP-9) are two proteins highly differentially expressed by malignant gliomas. We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers. Experimental Design: Serum samples were obtained concurrently with magnetic resonance imaging scans. YKL-40 and MMP-9 were determined by ELISA and the values correlated with the patient's radiographic status and survival. Results: High-grade glioma patients who underwent a surgical resection of their tumor had transient increase of both YKL-40 and MMP-9 serum levels in the postoperative period. Glioblastoma multiforme (GBM) patients with no radiographic evidence of disease (n = 10 patients, 50 samples) had a significantly lower level of YKL-40 and MMP-9 than patients with active tumor (n = 66 patients, 209 samples; P = 0.0003 and 0.0002, respectively). Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04). There was a significant inverse association between YKL-40 and survival in GBM, hazard ratio (hazard ratio, 1.4; P = 0.02), and anaplastic astrocytoma patients (hazard ratio, 2.2; P = 0.05). Conclusions: YKL-40 and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL-40 in anaplastic glioma patients. YKL-40 can be used as predictor of survival in patients with high-grade glioma. Longitudinal studies with a larger patient population are needed to confirm these findings. © 2006 American Association for Cancer Research. |
| Keywords: | immunohistochemistry; adult; cancer survival; controlled study; human tissue; aged; aged, 80 and over; middle aged; cancer surgery; survival rate; unclassified drug; major clinical study; case-control studies; cancer risk; nuclear magnetic resonance imaging; glioma; cancer grading; prospective studies; biological marker; protein blood level; gelatinase b; tumor markers, biological; enzyme linked immunosorbent assay; scleroprotein; longitudinal studies; glioblastoma; autoantigens; oligodendroglioma; astrocytoma; glycoproteins; growth substances; matrix metalloproteinase 9; protein ykl 40 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 12 |
| Issue: | 19 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2006-10-01 |
| Start Page: | 5698 |
| End Page: | 5704 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-06-0181 |
| PUBMED: | 17020973 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 46" - "Export Date: 4 June 2012" - "CODEN: CCREF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
11Gu -
576De Angelis -
203Stubblefield -
45
Edgar -
115Karimi -
225Holland -
49
Hormigo -
512Panageas -
312Fleisher -
4
Tanwar
Related MSK Work